Evidence map›Paper›PMID 40859026›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Molecular imaging based spatiotemporal dynamics progression of brain glucose metabolism in multiple system atrophy.

Xiaofeng Dou, Jing Wang, Daoyan Hu, Haotian Wang, Congcong Yu, Rui Zhou, Xiaohui Zhang, Qiong Yao, Mei Tian, Hong Zhang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaofeng Dou *Department of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jing Wang *Department of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Daoyan Hu *Department of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Haotian Wang *Department of Neurology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Congcong YuDepartment of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Rui ZhouDepartment of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiaohui ZhangDepartment of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Qiong YaoDepartment of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Mei TianHuman Phenome Institute & Huashan Hospital, Fudan University, Shanghai, China. tianmei@fudan.edu.cn.
Hong ZhangDepartment of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. hzhang21@zju.edu.cn.ORCID 0000-0002-4084-5150
Yan ZhongDepartment of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. yanzhong@zju.edu.cn.
Chentao JinDepartment of Nuclear Medicine and PET-CT Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. chentao_jin@zju.edu.cn.

Funding

National Natural Science Foundation of China 82030049
6 · The paper itself

Abstract

objectiveMultiple system atrophy (MSA) is a progressive neurodegenerative disorder with complex clinical manifestations, which is essential for patient management and mechanistic understanding of MSA. In this study, we aimed to use disease progression modeling (SuStaIn model) to elucidate the in vivo spatiotemporal progression patterns of brain glucose metabolism in MSA patients, and investigate the differential profiles of clinical characteristics and dopaminergic function among the identified progression-related subtypes.

methodsA total of 192 participants (117 MSA patients [70 MSA-P, 47 MSA-C] and 75 healthy controls) who underwent [

resultsThe [

conclusionThis study for the first time used [ CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

BrainDisease ProgressionGlucoseMolecular ImagingMultiple System AtrophyAgedFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPositron-Emission TomographyRetrospective StudiesFluorodeoxyglucose F18GlucoseFDG PET imagingMultiple system atrophy (MSA)Progression-related subtypesSubtype-stage inference (SuStaIn)

Identifiers

PMID40859026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.